Method of induction of cell differentiation of malignant cells such leukemia
a technology of leukemia and cell differentiation, which is applied in the field of leukemia in mammals, can solve the problems of ozone therapy almost completely unknown, ozone and roi's may cause damage, and the mechanism behind this protein damage has not been fully elucidated, so as to induce cellular differentiation of leukemic cells and surprise antineoplastic effects
Inactive Publication Date: 2001-12-06
SMITH LISA MARLENE JEFFERYS
View PDF0 Cites 1 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
0016] It is an object of the present invention to overcome the deficiencies in the prior art treatments of mammals suffering from leukemia such as CML. In accordance with one aspect of the present invention, there is provided a therapy which results in surprising antineoplastic effects in the treatment of leukemia such as CML. More
Problems solved by technology
The lack of published data regarding controlled trials as well as mechanisms of explaining it's actions have made ozone therapies almost completely unknown in North America.
The mechanisms behind this protein damage have not been fully elucidated.
However, it is theorized that ozone and ROI's may cause damage by removing or damaging tyrosine contained in proteins, or by signalling the cell to stop production of protein tyrosine kinases or inhibit the protein tyrosine kinase function which is important for signal transduction as it leads to cell proliferation in normal and transformed cells.
However, the use of ozone and ROI's as an agent in the treatment of cancer has been limited.
However, Sartori's experiments were concerned with the treatment of 12 lymphoma cases and several of the patients had other complications including AIDS and other cancers.
Indeed, clear conclusions were difficult to draw from the Sartori cases as they were not part of a proper control clinical trial and several of the patents also received chemotherapy.
None of these studies have examined the effects of ROI's on the immune and hematopoietic systems with respect to cancer and the leukemias.
The accumulation of these alkyl-lysophospholipids such as ET-18-OCH.sub.3, interferes with normal phospholipid metabolism and membrane composition resulting in damaged membranes.
Other cancer therapies have focused on bone marrow transplants, but despite improvement of allogenic bone marrow transplant technologies as a means to combat the leukemias, no therapies are currently available for patients who lack a bone marrow donor.
Typical maintenance agents such as interferon and hydroxyurea have shown some survival advantage but these therapies are by no means curative.
In addition, the toxic side effects of "conventional" chemotherapeutic agents significantly decreases the quality of life, while not necessarily extending it.
Once the patient enters the terminal phase of the disease, called blast crisis, there are no treatment options available.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
example 2
[0077] In order to demonstrate the effects of the invention on leukemias, the K562 cell line as the experimental model for human CML was chosen, and used peripheral blood mononuclear cells (PBMC) from normal patients as the controls. The final stages of leukemia known as `blast crisis` has extremely high concentrations of primitive (pluripotent) progenitor stem cells (FIG. 12). The K562 is a self renewing cell line which was established from a female patient with CML, in terminal blast crisis. As a result, the K562 cell line is composed of highly undifferentiated primitive progenitor cells that are not committed to any particular cell line series (FIG. 12). Furthermore, the K562 spontaneously produce recognizable progenitors of the granulocytic, monocytic and erythrocytic series. Therefore, the K562 cell line is a reasonable model to use for the study of human leukemias.
1. Materials and Methods
[0078] Ozone and ROI's were generated using medical grade oxygen from a high voltage coron...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
| Property | Measurement | Unit |
|---|---|---|
| Specific volume | aaaaa | aaaaa |
| Specific volume | aaaaa | aaaaa |
| Weight | aaaaa | aaaaa |
Login to View More
Abstract
A method for treating malignant cells such as leukemia or chronic myeloid leukemia, in a mammal, comprising of administering to the mammal a leukemia therapeutically effective amount of reactive oxygen intermediates. A method of treating cancer in a mammal with cancer and modulating the mammal's immune system, comprising of administering to the mammal in need thereof a cancer therapeutically effective amount of reactive oxygen intermediates. A method of treating leukemia in a mammal with leukemia, comprising of administering to the mammal in need thereof a leukemia therapeutically effective amount of ozone into the mammal's blood and a leukemia therapeutically effective amount of ether lipids.
Description
BACKGROUND OF INVENTION[0001] 1. Field of Invention[0002] The invention relates to a method for treatment of leukemia in mammals, and more specifically chronic myeloid leukemia (CML), using reactive oxygen intermediates. Reactive oxygen intermediates are administered in a therapeutically effective amount to a mammal that has leukemia. The administration of reactive oxygen intermediates, and more specifically ozone, has been found to be particularly effective in the treatment of CML and on the modulation of the immune and hematopoietic systems of mammals having cancer.[0003] 2. Description of Prior Art[0004] Therapeutic usage of ozone has occurred in Europe for more than 50 years. The lack of published data regarding controlled trials as well as mechanisms of explaining it's actions have made ozone therapies almost completely unknown in North America.[0005] Ozone, reactive oxygen intermediates (ROI) or reactive oxygen species (ROS) are known to damage cell membranes and cell proteins...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K31/08A61K31/662A61K33/40
CPCA61K31/08A61K31/662A61K33/40A61K2300/00A61P35/02
InventorSMITH, LISA MARLENE JEFFREYS
OwnerSMITH LISA MARLENE JEFFERYS